Detalhe da pesquisa
1.
Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland.
Neurol Neurochir Pol
; 58(1): 112-119, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38251955
2.
Cognitive impairment and BDNF serum levels.
Neurol Neurochir Pol
; 51(1): 24-32, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28341039
3.
Corrigendum to "Cognitive impairment and BDNF serum levels" [Polish J. Neurol. Neurosurg. 51 (2017) 24-32].
Neurol Neurochir Pol
; 51(6): 537, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28818513
4.
Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients.
J Clin Med
; 10(9)2021 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33922368
5.
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.
Neurology
; 2021 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380749
6.
From mild cognitive impairment to Alzheimer's disease - influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up.
Neurol Neurochir Pol
; 43(4): 321-9, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19742390